The effects of respiratory motion on the tumor dose can be divided into the gradient and interplay effects. While the interplay effect is likely to average out over a large number of fractions, it may play a role in hypofractionated [stereotactic body radiation therapy (SBRT)] treatments. This subject has been extensively studied for intensity modulated radiation therapy but less so for volumetric modulated arc therapy (VMAT), particularly in application to hypofractionated regimens. Also, no experimental study has provided full four-dimensional (4D) dose reconstruction in this scenario. The authors demonstrate how a recently described motion perturbation method, with full 4D dose reconstruction, is applied to describe the gradient and interplay effects during VMAT lung SBRT treatments. Methods: VMAT dose delivered to a moving target in a patient can be reconstructed by applying perturbations to the treatment planning system-calculated static 3D dose. Ten SBRT patients treated with 6 MV VMAT beams in five fractions were selected. The target motion (motion kernel) was approximated by 3D rigid body translation, with the tumor centroids defined on the ten phases of the 4DCT. The motion was assumed to be periodic, with the period T being an average from the empirical 4DCT respiratory trace. The real observed tumor motion (total displacement ≤8 mm) was evaluated first. Then, the motion range was artificially increased to 2 or 3 cm. Finally, T was increased to 60 s. While not realistic, making T comparable to the delivery time elucidates if the interplay effect can be observed. For a single fraction, the authors quantified the interplay effect as the maximum difference in the target dosimetric indices, most importantly the near-minimum dose (D 99% ), between all possible starting phases. For the three-and five-fractions, statistical simulations were performed when substantial interplay was found. Results: For the motion amplitudes and periods obtained from the 4DCT, the interplay effect is negligible (<0.2%). It is also small (0.9% average, 2.2% maximum) when the target excursion increased to 2-3 cm. Only with large motion and increased period (60 s) was a significant interplay effect observed, with D 99% ranging from 16% low to 17% high. The interplay effect was statistically significantly lower for the three-and five-fraction statistical simulations. Overall, the gradient effect dominates the clinical situation. Conclusions: A novel method was used to reconstruct the volumetric dose to a moving tumor during lung SBRT VMAT deliveries. With the studied planning and treatment technique for realistic motion periods, regardless of the amplitude, the interplay has nearly no impact on the nearminimum dose. The interplay effect was observed, for study purposes only, with the period comparable to the VMAT delivery time.
INTRODUCTION
The challenge of tumors and other organs moving during radiation therapy is well documented and the history and current state of motion management techniques, as pertains to photon therapy, were recently reviewed by Korreman. 1 The effects of motion on the tumor dose can be broadly divided into the gradient (motion blur) and interplay effects. 2 In conventional 3D conformal radiation therapy delivered in many fractions of 1.8-2.0 Gy each, the goal is to deliver a homogeneous tumorcidal dose to the target. The gradient effect, historically first noted for this type of treatment, occurs with the occasional tumor excursion outside of the volume irradiated to a high, homogeneous dose. If the proper beam apertures are selected to encompass the entire volume potentially occupied by the target, the tumor will always be irradiated to the prescribed, relatively homogeneous dose, regardless of its motion path within the irradiated volume. However, in ablative type treatments such as stereotactic body radiation therapy (SBRT), 3 the target dose is deliberately highly inhomogeneous, with the cooperative lung treatment protocols specifying the maximum dose in the target volume between 15% and 40% higher than the prescription, RTOG 0813 (Ref. 4) being but one example. Under these circumstances, the moving tumor dose will depend on the exact nature of the motion, even when the tumor does not venture outside the properly defined target volume. This is still a purely spatial effect and it would take place regardless of whether the dose distribution is produced by the static beam apertures or by a dynamic delivery technique such as intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT). However the second effect, the interplay, has a temporal component and is associated only with dynamic deliveries. Respiratory motion can interfere with the dynamically changing beam parameters, most notably the MLC segments' shapes, to alter the target dose. The analogy between this process and the classic wave behavior, including the relative frequency dependence and the possibility for either constructive or destructive interference was aptly noted. 1, 5 For the homogeneously irradiated target volume, the interplay effect is relatively easy to define as any deviation of the tumor dose from the planned value in the presence of the dynamic delivery and motion. However, with the inhomogeneous target dose distribution, distinguishing between the gradient and interplay effects in an experiment for dynamic deliveries is more challenging. Since the gradient effect is purely spatial, while the interplay has a temporal component, the logical way to isolate the interplay effect is to analyze the dosimetric effect of the varying starting phase of the motion relative to the beam start time. 6 The motion effects in the presence of the IMRT delivery have been studied by many authors.
2, 6-14 Bortfeld et al. 7 predicted that the interplay effect would, for the most part, average out with the large number of fractions. However, it is not automatically the case with hypofractionated radiosurgerytype course of treatment (1-5 fractions). While target motion effects in IMRT have been studied extensively with both experimental and theoretical methods, VMAT is a newer modality, and so there are substantially fewer studies of interplay in VMAT, 6, 9, 12, 13 particularly for hypofractionated dose regimens. The theoretical studies, while elucidating, do not necessarily rely on the actual delivery sequences, as the linear accelerator controller may change the VMAT delivery timing compared to the treatment planning system (TPS) estimate. 15 Previous experimental studies have typically used laborintensive physical motion stages, while reporting motioninduced dose changes to a relatively small number of points, or a single plane. In the absence of full volumetric analysis, it is not possible to evaluate the dose-volume parameters most important for SBRT, such as the near-minimum target dose.
It was recently demonstrated that VMAT dose to a moving target in a patient can be accurately and easily reconstructed from a single measurement in a static helical diode array phantom, using a perturbation method, 16 which incorporates many of the advantages of both the experimental and theoretical motion studies reported previously. Measurementguided, motion-adjusted, high resolution (2-3 mm voxel) volumetric dose data on a patient are available for display and analysis with conventional treatment planning tools. For any given treatment plan, only a single measurement with a static phantom is needed to quantify the effects of any possible motion pattern.
In this paper, we show how this novel methodology can be applied to isolate and quantify the possible interplay influence on the target dose-volume histogram (DVH) between the respiratory motion and dynamic VMAT delivery for lung SBRT treatments.
MATERIALS AND METHODS

2.A. Treatment planning and delivery
Ten consecutive patients previously treated with VMAT lung SBRT were selected, starting with the most recent one at the time of writing and working backwards. Each plan dealt with a single lesion. Half of the patients had their tumors in the upper lung lobes and the other half in the lower. All patients were treated with 6 MV photons on Varian Trilogy or TrueBeam linear accelerators (Varian Medical Systems, Palo Alto, CA) equipped with 120-leaf Millennium MLCs (5 mm leaf width in the central region). The beam characteristics of the different machines were closely matched (<1% differences in dose distributions). Four-dimensional helical CT (4DCT) datasets obtained on a Brilliance Big Bore scanner (Philips Medical Systems, Cleveland, OH) and reconstructed with a 3 mm slice width were used for treatment planning. The untagged low-pitch scan was used for dose calculations. The institutional practice for VMAT lung SBRT is to use 2-3 approximately half-arcs, avoiding beam entrance from the contralateral side. All patients were treated in five fractions to 50 or 60 Gy prescribed to 95% of the planning target volume (PTV). The internal target volume (ITV) was defined as the union of the visible gross tumor volumes (GTVs) with no added margins for microscopic extension, from all the different phases of 4DCT. The PTV is derived by a uniform 5 mm expansion of the ITV. Treatment planning was done on Pinnacle treatment planning system (TPS) v. 9.2 (Philips Radiation Oncology Systems, Fitchburg, WI). Dose calculations were performed on a 3 mm grid and 4
• VMAT control points (CP) spacing 15 with the Collapsed Cone Convolution algorithm. For the target motion effect analysis, first the original treatment plans were used. Additionally, those plans were modified to accommodate the expanded simulated motion, as described below.
2.B. Motion kernels
2.B.1. Original empirical motion kernels
The current institutional practice is to allow VMAT treatments for lung SBRT tumors that move less than 1 cm. The average tumor excursion was 4 ± 2 mm (1 SD), with the range of 1-8 mm. For the purposes of this study, the tumor motion is assumed to be a 3D rigid body translation. 17 Therefore, the tumor motion pattern (motion kernel) can be defined as a plot of the tumor centroid position against time, discretized in practice according to the ten 4DCT phases. The tumor was defined as a physician-drawn GTV on a single 4DCT phase (GTV0 by convention, Fig. 1 ). The GTV0 volumes ranged from 0.9 to 17.2 cm 3 [average 6.8 ± 5.1 (1 SD) cm 3 ]. Using deformable registration in the Mirada RTx software package v.1.2 (Mirada Medical Ltd, Oxford, UK), this contour was propagated to the remaining nine phases. The centroids of the resulting volumes were taken as the tumor centroid locations on every phase, providing the spatial component of the original empirical motion kernel. The temporal component was based on the periodic tumor motion assumption, with the average period of the breathing trace from the 4DCT [average among the patients 3.5 ± 0.8 (1 SD) s, range 2.9-4.6 s].
A union of the original tumor volumes situated on all phases following the centroid excursion represented the ITV. Since the ITVs on which the original PTVs and plans were based were obtained by differing procedures, the tumor volume was slightly adjusted so that the boundaries of the new ITV were within 1 mm of the original plan ITV.
2.B.2. Simulated extended motion
Additional motion kernels simulated larger motion (2 or 3 cm total target excursion). For each patient, the original motion trajectory was proportionately expanded to result in the total tumor displacement of 2, and then 3 cm. When necessary, the direction of the motion was adjusted to avoid unrealistic patterns such as tumor incursion into the chest wall. The predominantly superior-inferior (SI) motion direction was maintained. A new, expanded, ITV and PTV were constructed as described above, and the patients were replanned to ensure the new PTV prescription dose coverage at the 95% volume level. Since the 2 or 3 cm tumor motion is not reflected in the planning CT densities, the ITV density was manually overridden with the value of 0.8 relative to water. The necessity and validity of this approximation are elaborated in Sec. 4 .
The modified treatment plans used the same objectives as the original ones, but additionally, the RTOG intermediate dose compactness and symmetry criteria (50% dose volume to PTV volume ratio, and maximum dose 2 cm from the PTV in any direction) (Ref. 4) were enforced. This resulted in higher modulation and, subsequently, dose inhomogeneity in the expanded ITVs compared to the original ones, which, if anything, should accentuate the findings of this paper. The maximum PTV dose was 15%-40% higher than the prescription, conforming to the RTOG protocols specifications. 4 These plans were evaluated for motion effects first with the original 4DCT motion periods, and then with the 60 s period. While not realistic, making the motion period comparable to the delivery time helps to evaluate the causes of the interplay effect.
2.C. Data collection and analysis
2.C.1. Dose to the moving target
Measurement-guided dose estimate to a moving target in a patient is based on a research version of the commercial 3DVH software package (Sun Nuclear Corp., Melbourne, FL). For the static dose distribution, the basic premise of the 3DVH algorithm is that the volumetric dose on the patient can be estimated by perturbing the patient TPS dose distribution based on the phantom measurements. 18 The dosimetry phantom used for VMAT beams is the helical ArcCHECK diode array (Sun Nuclear), with its calibration formalism described by Kozelka et al. 19 The accuracy of the 3DVH static 3D dose reconstruction on an arbitrary CT dataset, from a measurement on a homogeneous cylindrical phantom, was demonstrated for both homogeneous 18 and inhomogeneous (anthropomorphic thoracic) (Ref. 20) phantoms representing a patient. In this study, the QA method described above was used to confirm the agreement between planned and delivered 3D dose distributions on the patients. Gamma analysis with rather stringent 2%/2 mm (local dose-error normalization) criteria was used.
As demonstrated by Feygelman et al., 16 the planned dose perturbation concept can be extended to the dynamic (4D) dose reconstruction. The fraction dose to any patient voxel in the presence of motion, assuming the motion kernel is known, can be derived by applying a measurement-guided motion correction. The dose to the diodes in a helical phantom is recorded at 50 ms intervals and is transformed into a series of time-resolved high-density volumetric dose grids. A moving voxel is propagated through this 4D dose space and the fraction dose to that voxel moving in the phantom is accumulated. For every voxel, the ratio of this motion-perturbed, reconstructed dose to the TPS dose in the phantom is taken. This ratio serves as a perturbation factor, applied to the TPS fraction dose to the similarly situated voxel in the patient.
For any given plan, the effects of multiple motion kernels can be simulated after a single measurement. In the 3DVH software, the moving region of interest (ROI) is identified and a corresponding motion kernel (rigid 3D translation/rotation) is defined. An automatic margin equal to the diagonal of the TPS calculation grid voxel is added to the moving ROI to avoid ambiguity in scoring the border voxels as either static or moving. It is physically justified, as the voxels close to the border of a moving ROI are expected to move with a similar trajectory. 21 A motion perturbation is applied to every voxel inside the selected ROI within the margin. The moving ROI's centroid spatial coordinates can be typed in, or defined automatically as the centroids of appropriate ROIs. The motion simulation can be started at an arbitrarily defined time with respect to the beam starting moment, thus any starting phase can be simulated. A single fraction starting at any desired phase, a specified number of fractions with random starting phases, or a large number of fractions can be simulated in any given run. The motion-perturbed dose grid can be saved as a DICOM RT Dose object and displayed and analyzed with conventional tools.
2.C.2. Metrics
The main metric of significance for lung SBRT is the near minimum dose (D min ) to the target. 17 In the prior relevant publications, the minimum dose encompassing 99% of the ROI (D 99% ) was used to represent D min . 13, 17 On the other hand, ICRU report 83 (Ref. 22 ) recommends D 98% as the near minimum dose surrogate. Therefore, we investigated both and evaluated correlation between them. Similarly, D 1% and D 2% were used as the near maximum dose (D max ) metrics. Finally, the mean doses D mean were also recorded. When necessary, the dosimetric indices for the moving target are reported as differences from the corresponding metrics for the static ITV, thus eliminating the influence of the fraction prescription dose and the differences in the individual plans. Throughout the paper, we will use the term "target" to describe the moving tumor with its shape represented by GTV0. The term "ITV" will always refer to a static contour that is the union of the target volumes on all 4DCT phases.
2.C.3. Single and multiple fraction simulations
2.C.3.a. Single fraction.
For a single fraction, the interplay effect can be defined deterministically as the maximum difference in the moving target dose metrics calculated for one fraction for every possible pair of the available starting phases. Our methodology allows to define and measure interplay according to its fundamental characteristic-the difference in dose caused by the change in the motion starting phase in relation to the beam start time, 2 without resorting to surrogates. 8, 10, 12 For each motion kernel with a corresponding plan, a single fraction motion simulation was run six times, corresponding to every other starting phase (0%, 20%, . . . , 80%) plus 50%, out of ten available from 4DCT. The maximum spread in dosimetric indices is reported as an aggregate average between all patients, with corresponding ranges.
The subsequent analysis for the single fraction simulation is contingent upon the interplay magnitude. For those motion kernels where the interplay effect is small, the data for all starting phases can be averaged (i.e., interplay neglected) and, for a single fraction, the gradient effect can be quantified in isolation. The target dose indices are reported as differences from the corresponding static ITV values. The averages and ranges over the patient population are presented. When the interplay effect is appreciable, only a combined (gradient and interplay) motion effect can be easily discerned experimentally. The ranges of the target dosimetry indices in comparison with the ITV are presented for individual patients.
2.C.3.b. Multiple-fraction courses. Of the two motion effects, only the interplay depends on the number of fractions. 7 Therefore, only when significant interplay is found for a single fraction is an attempt to quantify the effect of fractionation warranted. Unlike for a single fraction, only a statistical estimate can be made. A simulation of three-and five-fraction treatment courses was run five times each, with random starting phases assigned to each fraction for each simulation. The range of dosimetry indices' values between the different runs is a measure of the interplay effect which is expected to diminish as the number of fractions increases. 7 The statistical multiple-fraction ranges for D 99% were compared to the deterministic single-fraction interplay-induced range caused by the different starting phases.
RESULTS
3.A. Single fraction
As a basic initial quality control measure, it was demonstrated that the 3D comparison between the measurementreconstructed and TPS-calculated dose distributions with 2%/2 mm gamma analysis for original plans resulted in >90% passing rate for each patient, with an average of 94.4 ± 2.7 (1 SD)%. It was also determined that the changes in D 99% and D 98% , as well as D 1% and D 2% correlated very closely for all plans and motion kernels (correlation coefficient >0.99 when compared across the patient sample). Therefore, only D 99% and D 1% data are presented in detail, for clarity and brevity.
In Fig. 2 , the interplay effect for a single fraction is essentially quantified.
The maximum percentage differences in dosimetric indices, between any two of the starting phases, are plotted as averages for the patient population with the corresponding ranges. For the original motion kernels obtained from 4DCT (≤8 mm motion, 3-5 s period), the effect is negligible (<0.2%). With the motion range increased to 2 or 3 cm, the maximum difference between the phases increases slightly: averaged between the patients, the D 99% interplay-induced spread is <1%, with the maximum range of 2.2%. Therefore, for the studied plans, the interplay effect is minimal within the clinical range of motion parameters. Once the motion period is artificially increased to 60 s, the interplay effect begins to increase, reaching its maximum for the 3 cm motion. At that point, the maximum difference in D min between two starting phases can be >20%.
Since for the realistic motion periods the dosimetric differences between the starting phases are small (Fig. 2) , for any given patient, the moving target doses can be averaged between all the phases (i.e., interplay neglected) before comparing to the static ITV. The results are plotted in Fig. 3 , representing predominantly the gradient effect. The differences are small for the original motion kernels. Once the motion range is increased to 2-3 cm, while maintaining the original period, the mean near-minimum target to ITV dose ratios increase, while near-maximum ones decrease, characteristic of the "motion blur." The balance of this dose change in the current study is such that the target D mean is almost always higher than for the static ITV. There are only three instances out of possible 20 when the target D mean for either 2 or 3 cm motion was lower than the static ITV one. This negative difference never exceeded 1%.
For the original motion amplitude with an artificial 60 s period, the motion-induced dose changes are still small. How- ever, in comparing Fig. 3 , the ranges for the original motion (<1 cm) to the original with increased period, the target nearminimum doses can now be slightly lower than for the static ITV, indicating some presence of the interplay. The maximum such difference observed for a single staring phase was −3.4% for D 99% .
With the 60 s period and 2-3 cm motion range, the interplay effect results in a substantial dependence of the fractional dose on the starting phase. Therefore, those data groups are omitted in Fig. 3 . Instead, the phase-dependent spreads of the single fraction target to ITV dosimetric indices differences are presented for individual patients in Fig. 4 . Those results vary greatly. For example, D 99% for the moving target can be anywhere from 16% low to 17% high compared to the static ITV.
As an example, locations of dose-differences ≥5% [a threshold used previously by Court et al. (Ref. 9) ] between starting phases of 0% and 50%, with 60 s motion period and 3 cm range, are presented for a single patient in Fig. 5 . No differences above 2% are seen for this patient with the same motion range but with the normal period of 4.2 s.
3.B. Multiple-fraction courses
The reduction in the interplay effect with increased number of fractions is illustrated in Fig. 6 , with D 99% chosen as an example. The deterministic ranges of D 99% differences between the moving target and static ITV, due to the starting phase variation in a single fraction, are compared to a statistical spread due to five simulations, with random starting phases, of the three-and five-fraction courses. For the 2 cm, 60 s simulated motion, the patient-population averages of ranges in Fig. 6   FIG. 6 . Reduction in interplay effect in D 99% with the number of fractions presented per patient (x-axis groups). The first data point in each group is the full range (deterministic) between all possible starting phases of the ratio of moving GTV0 D 99% to static ITV. The second and third ones are statistical means and ranges of the same ratios between five simulations with random starting phases of three-and five-fraction treatments, respectively. The last bar is the mean value for the large number of fractions (30) simulation. The motion period is 60 s and the range is 2 (a) or 3 cm (b).
were reduced from 7.1 ± 4.2 (1 SD)% for a single fraction, to 3.7 ± 1.7% and 2.2 ± 1.0%, for the three-and fivefraction courses, respectively. For the 3 cm, 60 s motion, the corresponding numbers were 8.4 ± 6.0%, 3.7 ± 1.9%, and 2.8 ± 1.6%. Repeat measures analysis of variance (ANOVA) indicated that overall these differences in mean ranges were statistically significant between the three fractionation schemes (p < 0.02). The post-test for individual pairs results in statistically significant differences between one and three or five fractions at the 95% confidence level, but no statistical difference between three and five fractions.
The mean value for a large number of simulations (30) can also be compared to the three-and five-fraction averages. The results for 2 and 3 cm motion with 60 s periods are similar. The average D 99% target vs ITV differences across ten patients deviated from the mean of 30 fractions by no more than 0.8 ± 1.1% and 0.2 ± 1.1% for the three-and five-fraction courses, respectively.
DISCUSSION
4.A. Dose to the moving target
It is clear from Fig. 2 that for the original 4DCT motion kernels (tumor excursion ≤8 mm, period 3-5 s), the interplay defined as the maximum spread of volumetric dosimetric indices between all possible starting phases is negligible. The studied interplay increases slightly with the motion range increase to 2-3 cm, reaching for D 99% an average value of 0.9% and the maximum of 2.2% among all the patients. A further slight increase is observed when the motion period is artificially set to 60 s. However, even in this hypothetical scenario, the D 99% is mostly higher for the target than the ITV, and is never lower by more than 1%. With the ITV dose being already higher than the prescription, the clinical effect would be negligible. This coincides with the conclusions from the computational study by Rao et al., 13 which used largely the same definition of interplay based on the near-minimum dose to the target. On the surface, an experimental RapidArc motion study by Court et al. 8 concludes that interplay can lead to appreciable changes in target dose. However, there are substantial methodology differences between the current study and that of Rao et al. 13 on the one hand, and Court et al. 8 on the other hand. In this work and Ref. 13 , the primary metric of interest is the near-minimum dose to the target in the patient. In Ref. 8, the dose differences are recorded in a single plane of a dosimetry array, making a DVH evaluation impossible. The metric was the percentage of the pixels in the target, which never had dose-errors larger than a certain criterion (3%-5%), regardless of the starting phase. It can be argued that for the lung SBRT target dosimetry the near-minimum dose is more clinically important than the exact dose distribution in the target. 17 With the differences in beam modulation caused by the planning objectives and ITV/PTV size changes when switching from the original to 2-3 cm motion, it is clear from Fig. 2 , that in order to observe a substantial interplay effect in the lung VMAT SBRT, two conditions must be met: the tumor excursion must exceed 1 cm, and the motion period must be comparable to the gantry rotational period. With the inverse of that period being one of the fundamental frequencies of the delivery system, this follows the observation by Kissick and Mackie 5 that the maximum interference (interplay effect) would occur when the machine fundamental motion frequency is comparable to the tumor fundamental motion frequency. The simulations by Li et al. 11 further confirm that the dose-error is a somewhat periodic function of both the delivery time and motion frequency.
Approximately two-thirds of the motion kernels had predominant tumor displacement in the SI direction, with the rest in the AP or LR directions. At the same time, nine out of ten patients had collimator angles between 8
• and 15
• , and one 30
• . Thus, a range of relative orientations of the leaf movement direction and tumor displacement 14 was explored, with essentially the same results. Still, it must be emphasized that our findings of low interplay effect should not be automatically extended to sites and techniques other than lung SBRT. Different optimization schemes, planning constraints, modulation levels, target sizes, and motion characteristics could lead to different results.
In Fig. 4 , the near-minimum target dose tends to be higher, and the near-maximum lower than the ITV. This is due to the bias induced by the gradient effect, which follows from simple geometrical considerations (Fig. 1) and represents the motion-induced averaging, or "blur." The interplay effect is superimposed on this gradient effect, resulting in the substantial range of the target dose values, depending on the starting phase. Interestingly, the mean target doses in Fig. 4 tend to be higher than the mean ITV dose. This manifestation of the gradient effect is not general but is rather a function of the intersection of the patient-specific dose distribution with the tumor position probability density function.
The quantitative comparison between the single-and multiple-fraction interplay effects is not as rigorous because we are trying to compare a deterministic quantity with statistical samples. Only a small number of statistical simulations were performed because of the limited practical significance of simulating unrealistically high motion periods. However, qualitatively, the interplay effect decreased as the number of fractions is increased to 3 or 5, in agreement with theoretical simulations. 7, 11 For the data in Fig. 6 , the maximum standard deviation of D 99% among the patients for five runs was reduced from 2.9% for three fractions to 1.9% for five fractions. Averaged between all runs for all patients, the three-and fivefraction D 99% did not deviate from the 30 fraction value by more than 0.8 ± 1.1% (1 SD) and 0.2 ± 1.2%, respectively. Similarly averaged D mean did not deviate from the 30-fraction value by more than 0.2 ± 0.8%, even with the unrealistically high interplay for a single fraction.
4.B. Assumptions
A number of assumptions were required to make this study feasible. First, the tumor motion is approximated by a rigid body translation, as necessitated by the current 3DVH software design. This subject was studied previously by Admiraal et al., 17 who concluded that the approximation was reasonable for a small tumor in the lung. Second, the tumor motion is assumed to be periodic. If anything, the periodic nature of motion is expected to exaggerate the interplay effect, and more random temporal motion patterns would not alter the findings for the realistic motion kernels (3-5 s per cycle). The 2 and 3 cm simulated motion ranges can be characterized as "top of the range" and "exceedingly large," respectively, for a lung tumor. [23] [24] [25] Finally, we had to assign a uniform density to the ITV for extended motion (2-3 cm) simulations. Even when 4DCT information is used for target definition, dose calculations are routinely performed on an average 3D CT dataset, 17, 26 which can be either a mathematical average of the reconstructed phases or a physical slow (low-pitch), untagged scan. While it results in acceptable, if not negligible, dosimetric errors for real patient CT datasets, except perhaps at the PTV margins, 27 in our case of simulated extended motion, the large portions of the ITV not visited by a real tumor, exhibit unrealistically low (lung) CT density. This interferes with the perturbation algorithm's ability to accurately reconstruct dose to the moving target. Since in this study we are interested only in relative dose changes due to the target motion within the ITV, the exact average ITV density is not important, as long as it is reasonably high. We verified that the presented numerical results are negligibly (<0.2%) affected by the ITV density variations relative to water from 0.5 to 1.0, which should encompass the range of average ITV CT densities encountered in real life.
CONCLUSIONS
We applied a motion perturbation method to reconstruct the volumetric dose to a moving tumor during lung SBRT VMAT deliveries. The possible effect of interplay between the tumor motion and dynamic dose delivery was evaluated and separated from the gradient effect that depends only on the tumor position probability density function and 3D dose distribution, and is present regardless of the delivery dynamics. With the studied planning and treatment technique, for realistic motion periods (3-5 s), and regardless of the motion amplitude, the interplay has nearly no impact on the most important target dose metric in lung SBRT-the near-minimum dose. Thus, while motion management techniques may serve useful clinical purpose, such as reducing the amount of irradiated healthy lung, the target dosimetry alone does not warrant attempts to reduce the motion amplitude. The conclusions about the importance of the interplay can differ for different treatment sites, techniques, and optimization algorithms, while the manifestation of the effect may depend on the data acquisition methods, analysis metrics, and the specific definition of the interplay.
The interplay effect was observed, for study purposes only, with the substantial tumor motion and unrealistically long period (60 s), comparable to the VMAT delivery time. The effect of motion on the target DVH for an individual patient can be further determined based on the experimental VMAT delivery pattern recorded during a routine QA session and 4DCT motion kernel. Future application of this method to nonrigid motion is a matter of programming an interface that would track individual voxels through the 4D dose space in the presence of organ deformation.
